JPMorgan raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $49 from $48 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Buy Rating Driven by Anticipated Phase 3 Trial Results for Olezarsen
- Ionis Pharmaceuticals: Hold Rating Amidst Competitive Challenges and Pricing Uncertainties
- Ionis Pharmaceuticals’ Strategic Advantage in the HAE Market with DAWNZERA Approval
- Ionis Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright
- Ionis Pharmaceuticals price target raised to $65 from $62 at Piper Sandler